Home/Filings/4/0001415889-24-019908
4//SEC Filing

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 4

Accession 0001415889-24-019908

CIK 0001817241other

Filed

Jul 21, 8:00 PM ET

Accepted

Jul 22, 8:28 PM ET

Size

9.4 KB

Accession

0001415889-24-019908

Insider Transaction Report

Form 4
Period: 2024-07-22
Transactions
  • Conversion

    Series B Preferred Stock

    2024-07-22145,0890 total
    Common Stock (145,089 underlying)
  • Conversion

    Common Stock

    2024-07-22+145,089145,089 total
  • Other

    Common Stock

    2024-07-22$10.20/sh+49,019$499,994194,108 total
Footnotes (2)
  • [F1]Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date.
  • [F2]Represents the conversion of outstanding simple agreement for future equity in the amount of $500,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.

Issuer

Artiva Biotherapeutics, Inc.

CIK 0001817241

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001787092

Filing Metadata

Form type
4
Filed
Jul 21, 8:00 PM ET
Accepted
Jul 22, 8:28 PM ET
Size
9.4 KB